FDA Pediatric Exclusivity Runs on a Written Request — Not PREA’s Mandate

Pediatric regulatory conversations tend to collapse two different statutes into one. PREA requires a pediatric assessment before FDA will act on many marketing applications, absent a waiver or deferral — that is a mandate. The Best Pharmaceuticals for Children Act runs on a different lever entirely: FDA asks, the sponsor decides, and the reward is six months of exclusivity if the resulting studies fairly respond to the request. Confusing the two leads teams to either overbuild a voluntary program to a mandatory standard, or treat a genuine incentive opportunity as an obligation they can defer indefinitely.

The Written Request is the whole mechanism

BPCA, codified at 21 U.S.C. § 355a, gives FDA authority to identify a drug that could benefit from pediatric study and issue a Written Request to the application holder describing the studies FDA wants and the timeframe for completing them. The Food and Drug Administration Safety and Innovation Act made this authority permanent in July 2012, ending the periodic reauthorization cycle the program ran under for its first decade. Everything downstream of the Written Request — whether the sponsor studies the drug, what it studies, and whether FDA grants the exclusivity — traces back to that one document.

Voluntary, and not conditioned on a positive result

Two features separate BPCA from most exclusivity mechanics in the FD&C Act. First, the studies are voluntary: a sponsor that receives a Written Request can accept it, decline it, or ask FDA to amend the scope or timeline — there is no penalty for declining, because there was never an obligation to begin with. Second, FDA's decision to grant exclusivity does not turn on whether the studies showed the drug works in children, or on whether the sponsor files for a new pediatric indication. The statute's test is narrower: did the studies fairly respond to what the Written Request asked for. A well-designed, properly executed study that answers the question FDA posed can earn the exclusivity whether the result is positive, negative, or inconclusive on efficacy — and FDA approval of pediatric labeling is not itself a condition of the grant.

• Written Request issued. FDA identifies a drug that may benefit children and describes the pediatric studies and timeframe it wants.
• Sponsor responds — or doesn't. Acceptance, decline, or a request to amend the scope are all live options; nothing compels a response.
• FDA reviews for "fairly respond," not a result. The agency checks the completed studies against what the request asked for, not against a predetermined outcome.
• Exclusivity attaches to the existing stack. A qualifying grant adds six months to the drug's unexpired Orange Book-listed exclusivities — it creates no independent protection period of its own.

BPCA rewards answering FDA's question, not answering it favorably. That distinction is what makes a negative pediatric finding still worth six months of exclusivity. Why "fairly respond" is the operative standard

Where it overlaps — and doesn't — with PREA

PREA, at 21 U.S.C. § 355c, is the mandate: it requires a pediatric assessment for many new drug and biologic applications, built around the pediatric study plan FDA expects by end of Phase 2, unless the sponsor secures a waiver or deferral. It carries no exclusivity reward, because it is not an incentive — it is a condition of approval. BPCA and PREA frequently apply to the same drug at the same time, and FDA administers them through related but distinct processes; satisfying one does not satisfy the other, and a sponsor completing PREA-required studies is not automatically eligible for BPCA's exclusivity unless those studies were also the subject of a Written Request. Treating the two as interchangeable is the single most common pediatric-strategy error we see — usually surfacing as a program that assumes its mandatory PREA studies already banked the exclusivity, or one that declines a Written Request thinking it carries the same waiver mechanics PREA does.

BPCA also reaches beyond on-patent drugs: FDA, in consultation with the National Institutes of Health, maintains a process for issuing Written Requests on off-patent drugs that could still benefit from pediatric study, with NIH funding the resulting trials rather than the sponsor. That branch matters less to a commercial exclusivity calculus and more to the broader pediatric evidence base, but it is part of the same statutory mechanism. For a drug still inside its exclusivity window, the real work is lifecycle exclusivity strategy: modeling whether a Written Request's six-month add-on, layered onto whatever patent and non-patent protection remains, changes the economics enough to justify the pediatric program — a calculation that has nothing to do with whether PREA already has the company running pediatric studies on a separate, mandatory track. Where the two tracks genuinely diverge in a program, that gap is worth modeling before accepting or declining either one.